|
- Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases Learn more about Sarepta
- About Our Company | Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short
- Our Disease Areas | Sarepta Therapeutics
At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases Learn more about the disease areas we're focused on
- Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in . . .
Today, Sarepta Therapeutics notified the U S Food and Drug Administration (FDA) of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025
- Our Pipeline | Sarepta Therapeutics
Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology
- The Science Behind Our Precision Genetic Medicine Platforms | Sarepta . . .
Sarepta is pursuing the development of precision genetic medicine at the forefront of biotechnology for rare diseases: gene therapy, RNA-targeted exon skipping, and gene editing
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to . . .
Sarepta is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for ELEVIDYS
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline . . .
– After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets – Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36%
|
|
|